Geographic atrophy (GA) is a progressive, degenerative disease whose development is associated with modifiable and nonmodifiable risk factors, including mutations in specific genes involved in the regulation of the complement system. Multimodal imaging is crucial for the early diagnosis and determination of GA progression, with current recommendations highlighting optical coherence tomography as the primary imaging modality for detecting biomarkers associated with progression. Two novel therapies that target components of the complement system were approved by the FDA in 2023 allowing for personalized, long-term management of GA. In this CE activity, experts in the field review the latest imaging tools for the early diagnosis and monitoring of disease progression; evaluate clinical and imaging characteristics associated with disease progression in different phenotypes; and assess individualized treatment selection for patients with GA secondary to age-related macular degeneration (AMD). Rapid-Fire Roundtable discussion will further examine practical methods and procedures that can facilitate the optimal implementation of imaging modalities and therapies into the management of patient with GA secondary to AMD.

 

To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/ophthalmology/20241202/ga-secondary-to-amd-optimizing-long-term-outcomes-through-refined-treatment-selection